IHL : Pre-IND meeting granted with the US FDA regarding IHL-675A for use in preventing ARDS and SAARDS
The purpose of the meeting is to obtain regulatory guidance and agreement on the most efficient clinical development plan to… Read more
The purpose of the meeting is to obtain regulatory guidance and agreement on the most efficient clinical development plan to… Read more
Highlights: • Firm commitments received to raise A$11 million with strong demand from existing and new investors • Investment commitments… Read more
Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’), is pleased to announce that it… Read more
Clinical stage cannabinoid development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’), is pleased to announce that it… Read more